化合物 T16085
| 中文名称 | 化合物 T16085 |
|---|---|
| 中文同义词 | 化合物 T16085 |
| 英文名称 | L-000845704 |
| 英文同义词 | L-000845704;MK-0429;HGFOOLONGOBCMP-IBGZPJMESA-N;3-Pyridinepropanoic acid, 6-methoxy-β-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1-imidazolidinyl]-, (βS)-;MK-0429 (L-000845704) |
| CAS号 | 227963-15-7 |
| 分子式 | C23H29N5O4 |
| 分子量 | 439.52 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 227963-15-7.mol |
| 结构式 |  |
化合物 T16085 性质
| 熔点 | 122 °C |
|---|---|
| 沸点 | 735.5±60.0 °C(Predicted) |
| 密度 | 1.36±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 二甲基亚砜：250 mg/mL（568.82 mM） |
| 形态 | 固体 |
| 酸度系数(pKa) | 4.19±0.10(Predicted) |
| 颜色 | 白色至米白色 |
|
αvβ1 1.6 nM (IC 50 , inhibition of fibronectin-binding ) |
αvβ3 2.8 nM (IC 50 , inhibition of vitronectin-binding) |
αvβ5 0.1 nM (IC 50 , inhibition of vitronectin-binding) |
αvβ6 0.7 nM (IC 50 , inhibition of LAP-binding) |
αvβ8 0.5 nM (IC 50 , inhibition of LAP-binding) |
α5β1 12.2 nM (IC 50 , inhibition of fibronectin-binding) |
MK-0429 (100 or 300 mg/kg, p.o., twice daily b.i.d., 2 weeks) reduces metastatic tumor colony formation and area in the lungs. MK-0429 is safe and efficacious in significantly decreasing melanoma metastasis in the lungs.
| Animal Model: | B6D2F1 hybrid female mice |
| Dosage: | 100 or 300 mg/kg |
| Administration: | P.o., twice daily (b.i.d.), 2 weeks |
| Result: | MK-0429 at 100 and 300 mg/kg reduced the number of metastatic tumor colonies by 64 and 57%, respectively, and the high dose also reduced the tumor area by 60% as compared to the vehicle [2] . |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-15102 | MK-0429 | 1 mg | 2045元 | |
| 2024/04/30 | HY-15102 | 化合物 T16085 MK-0429 | 227963-15-7 | 5mg | 4500元 |